This competition is now closed.
- SU2CCanada CSC Program Guidelines
- SU2CCanada CSC Call for Ideas
- SU2CCanada CSC Program Webinar Q&A
- SU2CCanada OICR Supplemental Funding Guidelines
New Research Grant Competition for Two Dream Teams to Conduct Groundbreaking Cancer Research Focused on Breast Cancer and Cancer Stem Cells
TORONTO – October 14, 2014– Stand Up To Cancer Canada (SU2C Canada), together with Canadian Breast Cancer Foundation (CBCF) with support from CIBC, Cancer Stem Cell Consortium (CSCC), Genome Canada, Canadian Institutes of Health Research (CIHR), and the Ontario Institute for Cancer Research (OICR), is pleased to announce that up to $22.6 million CAD is available to fund two separate cancer research Dream Teams to accelerate the pace of groundbreaking research to bring new treatments from the laboratory to patients faster. Funding for this research is provided by these SU2C Canada collaborators and from the SU2C telecast which aired on September 5 and appealed to the Canadian public to pledge support for cancer research, awareness and education.
Two Dream Team funding opportunities are available, one for translational research focused on breast cancer and the other on cancer stem cells:
- The Stand Up To Cancer Canada-Canadian Breast Cancer Foundation Breast Cancer Dream Team, will provide up to $6 million CAD over a four-year term and is funded by the Canadian Breast Cancer Foundation, with support from the CIBC, and by SU2C Canada. Ideas are invited for a translational cancer research project that will address critical problems in breast cancer patient care and include new therapeutic interventions for breast cancer that would be expected to reduce progression and improve overall survival.
- The Stand Up To Cancer Canada Cancer Stem Cell Dream Team will provide approximately $10.6 million CAD over a four-year term, with funds from the CSCC (through Genome Canada and CIHR) and SU2C Canada. The Call for Ideas seeks to support a single, integrated, and cohesive pan-Canadian team bringing together key stakeholders – researchers, clinicians, industry, nongovernmental organizations, and funders – with the goal of improving the outcomes of hard-to-treat cancers by focusing on the role of cancer stem cells and stem cell programs on resistance and treatment failure in cancer. The team will employ new tools of modern biology, with an emphasis on genomics.
- Additionally, the two qualifying Dream Teams mayeach receive supplementary funds up to $3 million over four years from OICR, to support clinical trial activities in the province of Ontario.
As the Scientific Partner of SU2C Canada, the American Association for Cancer Research International - Canada (AACR International – Canada) today issued Calls for Ideas, inviting the Canadian research community to assemble Dream Teams of the best scientists from across the country to work collaboratively in multi-disciplinary, multi-institutional teams. The research proposals will be reviewed by the SU2C Canada Scientific Advisory Committee (CSAC), which will be composed of leading researchers and co-chaired by Nobel Laureate Phillip A. Sharp, PhD, institute professor at the Massachusetts Institute of Technology (MIT) and David H. Koch Institute for Integrative Cancer Research at MIT, and Alan Bernstein, OC, PhD, FRSC, president and chief executive officer of the Canadian Institute for Advanced Research. In addition, to ensure a thorough review process, each funding opportunity will also use a specialized subcommittee to contribute to the review of the submitted applications.
Letters of Intent must be submitted by noon ET, Monday, Dec. 8, 2014, using the proposalCENTRAL website at https://proposalcentral.altum.com.
For general information on eligibility criteria, the application process, and other details about these Dream Team grants, visit www.aacrcanada.ca. Inquiries may be directed to the AACR International-Canada at 416-797-5366 or [email protected].